Prevention and treatment of respiratory syncytial virus infection in infants: an update.
Respiratory syncytial virus (RSV) is a serious pathogen causing significant mortality and morbidity, especially in premature infants and infants with chronic lung disease or significant congenital heart disease. Therapy for RSV infection is essentially supportive, although several new compounds are under investigation. Therefore, immunoprophylaxis to prevent severe RSV disease in high-risk infants assumes great significance. Palivizumab, a humanized monoclonal antibody to RSV, significantly reduces hospitalization in the first 6 months in premature infants born at less than 35 weeks, infants less than 24 months of age with chronic lung disease and requiring treatment in the last 6 months, and in children 24 months or younger with hemodynamically significant heart disease. A new ultrapotent anti-RSV antibody (MEDI-524) appears to be more effective in animals than palivizumab and is undergoing clinical evaluation. There has been considerable progress in the development of vaccines; namely subunit, live attenuated, genetically recombinant virus and polypeptide vaccines. Plasmid DNA vaccines coding for parts of the F and G surface glycoproteins and vaccinia vector vaccines are also being evaluated. Maternal immunization has the potential to prevent RSV disease in early infancy. RSV prophylaxis has seen tremendous progress in the last decade.
Venkatesh
Mohan Pammi
MP
Neonatal-Perinatal Medicine, Baylor College of Medicine, 6621 Fannin St., WT 6-104 Houston, TX 77030-2303, USA. mohanv@bcm.edu
Weisman
Leonard E
LE
D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy*; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D014611:Vaccination / Q000639:trends; D014765:Viral Vaccines / Q000276:immunology / Q000627:therapeutic use*
D014765:Viral Vaccines